HomepageMedicineFDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia Medicine FDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia admin Posted on September 28, 2024 Landmark FDA approval of Cobenfy represents the first new class of drugs indicated to treat schizophrenia in decades. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostWhy Do My Cats Farts Smell Like Eggs? Our Vet Explains Next PostChristian Louboutin Makes a Splash at Paris Fashion Week You Might Also Like Medicine US Pharma and Biotech Summit 2024: Bringing the Skillset of Generation Alpha to the Pharma Industry admin May 23, 2024 Medicine Pfizer Teams With American Cancer Society to Reduce Cancer Care Disparities admin February 8, 2024 Medicine Degron Therapeutics, Takeda Ink Exclusive License and Collaboration Agreement to Develop Molecule Degraders Targeting Multiple Indications admin May 25, 2024 Medicine Cencora VP of Emerging Therapies Discusses Cell & Gene Therapy Distribution Strategies admin May 4, 2024
Medicine US Pharma and Biotech Summit 2024: Bringing the Skillset of Generation Alpha to the Pharma Industry admin May 23, 2024
Medicine Pfizer Teams With American Cancer Society to Reduce Cancer Care Disparities admin February 8, 2024
Medicine Degron Therapeutics, Takeda Ink Exclusive License and Collaboration Agreement to Develop Molecule Degraders Targeting Multiple Indications admin May 25, 2024
Medicine Cencora VP of Emerging Therapies Discusses Cell & Gene Therapy Distribution Strategies admin May 4, 2024